Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00123643 |
Recruitment Status :
Completed
First Posted : July 25, 2005
Results First Posted : August 9, 2012
Last Update Posted : July 15, 2013
|
Sponsor:
St. Paul Heart Clinic
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Aaron S. Kelly, Ph.D., University of Minnesota - Clinical and Translational Science Institute
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Prevention |
Condition |
Type 2 Diabetes Mellitus |
Interventions |
Drug: rosiglitazone Drug: glyburide |
Enrollment | 36 |
Participant Flow
Recruitment Details | recruitment was performed at medical clinics |
Pre-assignment Details | patients taking thiazolidinediones or sulfonylureas were allowed to washout of these medications 30 days prior to randomization |
Arm/Group Title | Rosiglitazone | Glyburide |
---|---|---|
![]() |
[Not Specified] | [Not Specified] |
Period Title: Overall Study | ||
Started | 20 | 16 |
Completed | 20 | 16 |
Not Completed | 0 | 0 |
Baseline Characteristics
Outcome Measures
Adverse Events
Limitations and Caveats
Small sample size; unbalanced sex distribution between groups
More Information
Results Point of Contact
Name/Title:
Aaron S. Kelly, Ph.D.
Organization:
University of Minnesota
Phone:
612-626-3492
EMail:
kelly105@umn.edu
Responsible Party: | Aaron S. Kelly, Ph.D., University of Minnesota - Clinical and Translational Science Institute |
ClinicalTrials.gov Identifier: | NCT00123643 History of Changes |
Other Study ID Numbers: |
GSK2002-2 |
First Submitted: | July 21, 2005 |
First Posted: | July 25, 2005 |
Results First Submitted: | July 2, 2012 |
Results First Posted: | August 9, 2012 |
Last Update Posted: | July 15, 2013 |